Neuphoria Therapeutics (NEUP) Net Cash Flow (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Net Cash Flow of -$3.4 million for Q1 2026, down 126.95% year-over-year from $12.6 million in Q1 2025, and down 141.15% quarter-over-quarter from $8.3 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Net Cash Flow (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Net Cash Flow for 4 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 126.95% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at $1.5 million (down 83.04% YoY), while the FY2025 annual figure was $1.6 million, up 280.42% from the prior year.
- Net Cash Flow eased to -$3.4 million in Q1 2026 per NEUP's latest filing, from $8.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $12.6 million in Q1 2025 and bottomed at -$4.7 million in Q3 2024.
- Historically, Net Cash Flow has averaged $579288.7 across 4 years, with a median of -$1.5 million in 2024.
- Annual changes were most pronounced in 2024 — Net Cash Flow tumbled 306.38% — and 2025, when it surged 915.67%.
- Neuphoria Therapeutics' Net Cash Flow stood at $1.7 million in 2023, then sank by 306.38% to -$3.5 million in 2024, then soared by 338.13% to $8.3 million in 2025, then tumbled by 141.15% to -$3.4 million in 2026.
- Business Quant data shows NEUP's Net Cash Flow at -$3.4 million in Q1 2026, $8.3 million in Q4 2025, and -$546385.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 225.59 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | -3.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | 8.26 Mn |
| Dec 31, 2025 | 8.26 Mn |
| Sep 30, 2025 | -546,385.00 |
| Sep 30, 2025 | -546,385.00 |
| Jun 30, 2025 | -2.86 Mn |
| Jun 30, 2025 | -2.86 Mn |
| Mar 31, 2025 | 12.62 Mn |
| Mar 31, 2025 | 12.62 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Jun 30, 2024 | 4.11 Mn |
| Jun 30, 2024 | 4.11 Mn |
| Mar 31, 2024 | -1.55 Mn |
| Mar 31, 2024 | -1.55 Mn |
| Dec 31, 2023 | 1.68 Mn |
| Dec 31, 2023 | 1.68 Mn |